Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
In a recent move, E. Thomas Corcoran, a director at Phibro Animal Health Corp (NASDAQ:PAHC), purchased a significant amount of the company’s stock. According to a filing with the Securities and Exchange Commission, Corcoran acquired 5,000 shares of Class A Common Stock on February 24, 2025. The shares were bought at a weighted average price of $22.10, with prices ranging between $22.02 and $22.11. This transaction has increased Corcoran’s total holdings to 30,000 shares. The purchase comes as the stock has shown remarkable strength, delivering a 72.5% return over the past year, according to InvestingPro data.
The acquisition, valued at approximately $110,500, reflects Corcoran’s continued investment in the company, which specializes in pharmaceutical preparations. Phibro Animal Health, headquartered in Teaneck, New Jersey, remains a key player in the life sciences sector. The company maintains strong financial health with a current ratio of 3.2, while four analysts have recently revised their earnings estimates upward. InvestingPro analysis suggests the stock is currently trading above its Fair Value, with eight additional ProTips available for subscribers.
In other recent news, Phibro Animal Health Corporation reported earnings for the second quarter of fiscal year 2025, surpassing consensus estimates with revenue and adjusted earnings per share (EPS) exceeding projections by approximately 2% and 25%, respectively. This growth has been largely driven by the company’s Animal Health segment, which experienced an 11% increase, excluding new Medicated Feed Additives (MFA), and a 33% surge with their inclusion. Barclays (LON:BARC) responded by raising its price target for Phibro to $22 from $20, while maintaining an Underweight rating on the stock. The firm highlighted the significant impact of the new MFA portfolio on Phibro’s financial results.
Additionally, Phibro declared a quarterly cash dividend of $0.12 per share for both its Class A and Class B common stock, payable on March 26, 2025, to shareholders of record as of March 5, 2025. This dividend reflects the company’s financial strategy and confidence in its operations. Furthermore, Phibro expanded its board by appointing Joyce J. Lee as a new independent Class II director. Lee’s extensive experience in the animal health industry is expected to contribute positively to the company’s strategic direction. Her appointment is part of Phibro’s commitment to enhancing its governance and strategic oversight.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.